Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1499-1507

  Okada, Satoko ^a   Tokunaga, Eriko ^a   Kitao, Hiroyuki ^a   Akiyoshi, Sayuri ^a   Yamashita, Nami ^a   Saeki, Hiroshi ^a   Oki, Eiji ^a   Morita, Masaru ^a   Kakeji, Yoshihiro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PROGNOSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; INDEPENDENT VARIABLE; JAPANESE; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL;

BASE SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE;

EID: 84862527308     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2166-5     Document Type: Article

References (34)

1. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348:2339-47. (Pubitemid 36638109)
2. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer. 2004;4:814-9.
3. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171-82. (Pubitemid 34161138)
4. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med. 2002;8:571-6. (Pubitemid 35408215)
5. Callahan R, Cropp C, Sheng ZM, et al. Definition of regions of the human genome affected by loss of heterozygosity in primary human breast tumors. J Cell Biochem Suppl. 1993;17G:167-72.
6. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31:961-7.
7. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet. 1995;9:439-43.
8. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266:120-2. (Pubitemid 24345332)
9. Lancaster JM, Wooster R, Mangion J, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996;13:238-40. (Pubitemid 26000445)
10. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta. 2004;1654:105-22. (Pubitemid 38681204)
11. Miller BJ, Wang D, Krahe R, Wright FA. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet. 2003;73:748-67. (Pubitemid 37271880)
12. Staff S, Isola J, Tanner M. Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res. 2003;63:4978-83. (Pubitemid 37022634)
13. Beckmann MW, Picard F, An HX, et al. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer. 1996;73:1220-6. (Pubitemid 26162336)
14. Gonzalez R, Silva JM, Dominguez G, et al. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. Br J Cancer. 1999;81:503-9. (Pubitemid 29458806)
15. Hanby AM, Kelsell DP, Potts HW, et al. Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer. Int J Cancer. 2000;88:204-8.
16. Schmutzler RK, Bierhoff E, Werkhausen T, et al. Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. Int J Cancer. 1997;74:322-5. (Pubitemid 27321803)
17. Charef-Hamza S, Trimeche M, Ziadi S, et al. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer. Cancer Lett. 2005;224:185-91. (Pubitemid 40725840)
18. Silva JM, Gonzalez R, Provencio M, et al. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Res Treat. 1999;53:9-17. (Pubitemid 29123615)
19. Katsama A, Sourvinos G, Zachos G, Spandidos DA. Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. Cancer Lett. 2000;150:165-70. (Pubitemid 30125850)
20. Querzoli P, Albonico G, di Iasio MG, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat. 2001;66:135-42. (Pubitemid 32521419)
21. Yamashita T, Iwase H, Yamashita i, et al. Low frequency loss of heterozygosity in the BRCA1 region in Japanese sporadic breast cancer. Breast Cancer. 1996;3:167-72.
22. Hampl JA, Hampl M, Reiss G, Koch R, Saeger HD, Schackert HK. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients. Anticancer Res. 2004;24:281-90. (Pubitemid 38279720)
23. Cleton-Jansen AM, Collins N, Lakhani SR, et al. Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer. 1995;72:1241-4.
24. van den Berg J, Johannsson O, Hakansson S, Olsson H, Borg A. Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. Br J Cancer. 1996;74:1615-9. (Pubitemid 26386090)
25. Oda S, Oki E, Maehara Y, Sugimachi K. Precise assessment of microsatellite instability using high resolution fluores cent microsatellite analysis. Nucleic Acids Res. 1997;25:3415-20. (Pubitemid 27359214)
26. Tokunaga E, Oki E, Oda S, et al. Frequency of microsatellite instability in breast cancer determined by high-resolution fluorescent microsatellite analysis. Oncology. 2000;59:44-9. (Pubitemid 30435835)
27. Johnson SM, Shaw JA, Walker RA. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer. 2002;98:205-9. (Pubitemid 34150803)
28. Oki E, Baba H, Tokunaga E, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005;117:376-80. (Pubitemid 41429560)
29. Tokunaga E, Oki E, Kimura Y, et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat. 2007;101:249-57. (Pubitemid 46169878)
30. Tokunaga E, Kimura Y, Oki E, et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer. 2006;118:284-9. (Pubitemid 41779066)
31. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2010;11:138-48.
32. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-23. (Pubitemid 36842560)
33. Tutt AN, van Oostrom CT, Ross GM, van Steeg H, Ashworth A. Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation. EMBO Rep. 2002;3:255-60. (Pubitemid 34269519)
34. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA doublestrand breaks occurring between repeated sequences. EMBO J. 2001;20:4704-16. (Pubitemid 32848624)